Tumor‐associated carbohydrate antigens: A possible avenue for cancer prevention
暂无分享,去创建一个
John Sidney | Alessandro Sette | J. Sidney | A. Sette | S. Gendler | A. Franco | Sandra J Gendler | Yanfei Xu | Alessandra Franco | Yanfei Xu
[1] Yi Cao,et al. Thomsen-Friedenreich-related carbohydrate antigens in normal adult human tissues: a systematic and comparative study , 1996, Histochemistry and Cell Biology.
[2] J. Schlom,et al. Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer , 2005, Breast Cancer Research and Treatment.
[3] C. Borrebaeck,et al. The human repertoire of antibody specificities against Thomsen-Friedenreich and Tn-carcinoma-associated antigens as defined by human monoclonal antibodies , 2005, Cancer Immunology, Immunotherapy.
[4] R. Schreiber,et al. The three Es of cancer immunoediting. , 2004, Annual review of immunology.
[5] S. Gendler,et al. Designer Glycopeptides for Cytotoxic T Cell–based Elimination of Carcinomas , 2004, The Journal of experimental medicine.
[6] P. Cresswell,et al. Recent developments in MHC-class-I-mediated antigen presentation. , 2004, Current opinion in immunology.
[7] M. Suresh,et al. T cell recognition of a tumor-associated glycoprotein and its synthetic carbohydrate epitopes: stimulation of anticancer T cell immunity in vivo , 2004, Cancer Immunology, Immunotherapy.
[8] P. Cresswell,et al. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids , 2004, Immunogenetics.
[9] B. Walker,et al. Determinants of HIV-1 Mutational Escape From Cytotoxic T Lymphocytes , 2003, The Journal of experimental medicine.
[10] B. Longenecker,et al. Mucin 1-Specific Immunotherapy in a Mouse Model of Spontaneous Breast Cancer , 2003, Journal of immunotherapy.
[11] T. Eberlein,et al. Mammaglobin-A is a tumor-associated antigen in human breast carcinoma. , 2003, Surgery.
[12] Thierry Boon,et al. Tumor‐specific shared antigenic peptides recognized by human T cells , 2002, Immunological reviews.
[13] M. Cheever,et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] D. Hafler. Degeneracy, as opposed to specificity, in immunotherapy. , 2002, The Journal of clinical investigation.
[15] Thomas K. Hoffmann,et al. Identification of Cyclin B1 as a Shared Human Epithelial Tumor-Associated Antigen Recognized by T Cells , 2001, The Journal of experimental medicine.
[16] A Sette,et al. Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules. , 2001, Human immunology.
[17] S. Gendler,et al. Spontaneous adenocarcinoma mouse models for immunotherapy. , 2001, Trends in molecular medicine.
[18] M. Bertrand,et al. An overview of the MAGE gene family with the identification of all human members of the family. , 2001, Cancer research.
[19] R. Schreiber,et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.
[20] S. Gendler,et al. Transgenic MUC1 Interacts with Epidermal Growth Factor Receptor and Correlates with Mitogen-activated Protein Kinase Activation in the Mouse Mammary Gland* , 2001, The Journal of Biological Chemistry.
[21] John Sidney,et al. Measurement of MHC/Peptide Interactions by Gel Filtration , 1999, Current protocols in immunology.
[22] S. Hakomori,et al. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. , 2001, Advances in experimental medicine and biology.
[23] M. J. Tevethia,et al. Mice with Spontaneous Pancreatic Cancer Naturally Develop MUC-1-Specific CTLs That Eradicate Tumors When Adoptively Transferred1 , 2000, The Journal of Immunology.
[24] J. Sidney,et al. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism , 1999, Immunogenetics.
[25] H. Grey,et al. Fine specificity and MHC restriction of trinitrophenyl-specific CTL. , 1999, Journal of immunology.
[26] V. Apostolopoulos,et al. MUC1 and breast cancer. , 1999, Current opinion in molecular therapeutics.
[27] L. Cipolla,et al. Synthesis of T-antigen-containing glycopeptides as potential cancer vaccines , 1999 .
[28] M. Hollingsworth,et al. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. , 1998, Cancer research.
[29] G. Ferrara,et al. Molecular features of the hepatitis B virus nucleocapsid T‐cell epitope 18‐27: Interaction with HLA and T‐cell receptor , 1997, Hepatology.
[30] S. Hakomori. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. , 1996, Cancer research.
[31] C. Brander,et al. Peptide immunization in humans: a combined CD8+/CD4+ T cell‐targeted vaccine restimulates the memory CD4 T cell response but fails to induce cytotoxic T lymphocytes (CTL) , 1996, Clinical and experimental immunology.
[32] N. Cheung,et al. GD2 oligosaccharide: target for cytotoxic T lymphocytes , 1995, The Journal of experimental medicine.
[33] R. Henderson,et al. MUC‐1 Epithelial Tumor Mucin‐Based Immunity and Cancer Vaccines , 1995, Immunological reviews.
[34] L. Otvos,et al. Comparison of the effects of amino acid substitutions and beta-N- vs. alpha-O-glycosylation on the T-cell stimulatory activity and conformation of an epitope on the rabies virus glycoprotein. , 1995, Biochimica et biophysica acta.
[35] B. Moss,et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis , 1995, The Journal of experimental medicine.
[36] G Hermanson,et al. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. , 1995, Journal of immunology.
[37] F. Chisari,et al. Hepatitis B virus immunopathogenesis. , 1995, Annual review of immunology.
[38] A. Sette,et al. Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope , 1994, The Journal of experimental medicine.
[39] A. Sette,et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells , 1994, Nature.
[40] F. Sallusto,et al. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha , 1994, The Journal of experimental medicine.
[41] P. Bruggen,et al. Tumor antigens recognized by T lymphocytes. , 1994, Annual review of immunology.
[42] D. Wiley,et al. The antigenic identity of peptide-MHC complexes: A comparison of the conformations of five viral peptides presented by HLA-A2 , 1993, Cell.
[43] T. Muramatsu,et al. Carbohydrate signals in metastasis and prognosis of human carcinomas. , 1993, Glycobiology.
[44] A. Vitiello,et al. Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein , 1993, Journal of virology.
[45] P. Parham,et al. Peptide binding to major histocompatibility complex molecules. , 1993, Annual review of cell biology.
[46] William S. Lane,et al. Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle , 1992, Nature.
[47] O. Blumenfeld,et al. O-linked oligosaccharides of glycophorins A and B in erythrocytes of two individuals with the Tn polyagglutinability syndrome. , 1992, Blood.
[48] J. Sacchettini,et al. Crystal structure of the major histocompatibility complex class I H-2Kb molecule containing a single viral peptide: implications for peptide binding and T-cell receptor recognition. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[49] P. A. Peterson,et al. Emerging principles for the recognition of peptide antigens by MHC class I molecules. , 1992, Science.
[50] S. Poppema,et al. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen. , 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.
[51] D. Wiley,et al. HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[52] D. Wiley,et al. Peptide binding to the major histocompatibility complex molecules: Current Opinion in Structural Biology 1992, 2:300–304 , 1992 .
[53] V. Stewart,et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement , 1992, Cell.
[54] R. Cardiff,et al. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.
[55] T. Ørntoft,et al. Nuclear volume and expression of T‐antigen, sialosyl‐Tn‐antigen, and Tn‐antigen in carcinoma of the human bladder. Relation to tumor recurrence and progression , 1992, Cancer.
[56] H. Rammensee,et al. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules , 1991, Nature.
[57] D. Wiley,et al. Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 A resolution. , 1991, Journal of molecular biology.
[58] S. Hakomori,et al. Induction of alpha-N-acetylgalactosamine-O-serine/threonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice. , 1991, Cancer research.
[59] E. Coligan. Current protocols in immunology , 1991 .
[60] N. Peat,et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. , 1990, The Journal of biological chemistry.
[61] M. Madej,et al. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. , 1990, Cancer research.
[62] S. Hakomori,et al. Molecular changes in carbohydrate antigens associated with cancer , 1990, BioEssays : news and reviews in molecular, cellular and developmental biology.
[63] M. Bevan,et al. Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization , 1989, The Journal of experimental medicine.
[64] W. Grossman,et al. Human lung carcinoma monoclonal antibody specific for the Thomsen-Friedenreich antigen. , 1989, Cancer research.
[65] S. Hakomori,et al. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. , 1989, Advances in cancer research.
[66] Y. Kim,et al. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. , 1989, Cancer research.
[67] A. M. Wu,et al. The Molecular Immunology of Complex Carbohydrates , 1988 .
[68] P. Parham,et al. Nature of polymorphism in HLA-A, -B, and -C molecules. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[69] K. Carraway,et al. Mechanism of expression of Thomsen‐Friedenreich (T) antigen at the cell surface of a mammary adenocarcinoma , 1988, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[70] C. A. Roberts,et al. Discussion * , 1970, Proceedings of the ASIL Annual Meeting.
[71] G. Springer. T and Tn, general carcinoma autoantigens. , 1984, Science.
[72] Cellular and Humoral Aspects of the Hypersensitive States , 1959, Pediatrics.
[73] M BURNET,et al. Cancer—A Biological Approach* , 1957, British medical journal.
[74] M. Burnet. Cancer—A Biological Approach , 1957, British medical journal.